Clinical advances of hypoxia-activated prodrugs in combination with radiotherapy
With the increasing incidence of cancer worldwide, the need for specific, effective therapies is ever more urgent. One example of targeted cancer therapeutics is hypoxia-activated prodrugs (HAPs), also known as bioreductive prodrugs. These prodrugs are inactive in cells with normal oxygen levels but...
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Journal article |
| Argitaratua: |
Elsevier
2017
|